A Belatacept Compassionate Use Study for Patients With a Kidney Transplant
Status:
Approved for marketing
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To make belatacept available for recipients of a renal allograft who are currently intolerant
to or have contraindications to CNIs and/or m-TOR inhibitors and are either:
- unable to construct an adequate immunosuppression regimen due to non-renal toxicity /
contraindication (and withdrawing the causative agent would lead to renal graft loss)
OR
- at imminent risk of losing the allograft kidney due to nephrotoxicity and have no other
options for renal replacement therapy